Literature DB >> 16538643

Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers.

Kuo-Chien Tsao1, Tsu-Lan Wu, Pi-Yueh Chang, Ji-Hong Hong, James T Wu.   

Abstract

A total of 73,443 asymptomatic individuals were screened on a voluntary basis for cancer at Chang Gung Memorial Hospital in Taiwan using a panel of tumor markers, including alpha fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromogranin A (CgA), and squamous cell specific antigen (SCC). The results are derived from data collected from January 1998 to October 2003. A total of 210 cancers (approximately 0.3%) were detected, including cancers of the liver, lung, colon, prostate, stomach, pancreas, breast, cervix, ovary, and bladder. Of the tumor markers monitored, elevated CA 19-9, CEA, and CA 125 were the most frequently detected in a variety of cancers. It was surprising to find that many cancers were not detected by their dominant markers but by the elevation of tumor markers not recommended for monitoring their tumor activity. Screening with multiple circulating tumor markers provides improved sensitivity for cancer detection in asymptomatic individuals before they reach the fatal advanced stage. Screening with multiple tumor markers also allows cancers to be detected in the absence of their dominant markers. If we had not measured the multiple tumor markers, these cancers would have gone undetected. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16538643      PMCID: PMC6807504          DOI: 10.1002/jcla.20102

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  10 in total

1.  Array-based ELISAs for high-throughput analysis of human cytokines.

Authors:  M D Moody; S W Van Arsdell; K P Murphy; S F Orencole; C Burns
Journal:  Biotechniques       Date:  2001-07       Impact factor: 1.993

2.  Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases.

Authors:  T L Wu; C P Chang; K C Tsao; C F Sun; J T Wu
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

3.  OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.

Authors:  C van Haaften-Day; Y Shen; F Xu; Y Yu; A Berchuck; L J Havrilesky; H W de Bruijn; A G van der Zee; R C Bast; N F Hacker
Journal:  Cancer       Date:  2001-12-01       Impact factor: 6.860

4.  Expression of monoclonal antibody-defined tumor markers in four carcinomas.

Authors:  J T Wu
Journal:  Ann Clin Lab Sci       Date:  1989 Jan-Feb       Impact factor: 1.256

5.  Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.

Authors:  J T Wu; A J Erickson; K C Tsao; T L Wu; C F Sun
Journal:  Ann Clin Lab Sci       Date:  2000-04       Impact factor: 1.256

6.  Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients.

Authors:  J T Wu; M E Astill; G H Liu; R A Stephenson
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

7.  Simultaneous multianalyte ELISA performed on a microarray platform.

Authors:  R Wiese; Y Belosludtsev; T Powdrill; P Thompson; M Hogan
Journal:  Clin Chem       Date:  2001-08       Impact factor: 8.327

8.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.

Authors:  W J Catalona; D S Smith; T L Ratliff; K M Dodds; D E Coplen; J J Yuan; J A Petros; G L Andriole
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

9.  Enthusiasm for cancer screening in the United States.

Authors:  Lisa M Schwartz; Steven Woloshin; Floyd J Fowler; H Gilbert Welch
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

10.  CA 125 elevations in patients with malignant lymphomas.

Authors:  T Fehm; E Beck; T Valerius; M Gramatzki; W Jäger
Journal:  Tumour Biol       Date:  1998
  10 in total
  3 in total

1.  Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.

Authors:  Kuo-Chien Tsao; Ji-Hong Hong; Tsu-Lan Wu; Pi-Yueh Chang; Chien-Feng Sun; James T Wu
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

2.  Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.

Authors:  Hsin-Yao Wang; Chia-Hsun Hsieh; Chiao-Ni Wen; Ying-Hao Wen; Chun-Hsien Chen; Jang-Jih Lu
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

3.  A Diagnostic Analysis Workflow to Optimal Multiple Tumor Markers to Predict the Nonmetastatic Breast Cancer from Breast Lumps.

Authors:  Nan Jiang; Tian Tian; Xianyang Chen; Guofen Zhang; Lijie Pan; Chengping Yan; Guoshan Yang; Lili Wang; Xuchen Cao; Xin Wang
Journal:  J Oncol       Date:  2021-07-08       Impact factor: 4.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.